Abstract
Baseline serum extracellular vesicle microRNA-1-3p (EV-miR-1-3p) serves as a protective biomarker for stratifying hepatocellular carcinoma (HCC) risk and predicting survival in chronic hepatitis C (CHC) patients after hepatitis C virus (HCV) eradication via direct-acting antiviral (DAA) therapy.
Introduction
The introduction of direct-acting antivirals (DAAs) has transformed the treatment landscape for Chronic Hepatitis C (CHC), enabling sustained virologic response (SVR)—effectively a cure—in nearly all patients. However, achieving SVR does not entirely eliminate the risk of hepatocellular carcinoma (HCC). Residual liver damage, cirrhosis, and persistent epigenetic modifications mean that a subset of patients remains at risk for developing liver cancer years after the virus has been cleared.
Currently, clinical surveillance relies on the FIB-4 index and alpha-fetoprotein (AFP) levels. While useful, these tools often lack the necessary sensitivity and specificity to accurately identify high-risk individuals in the post-SVR era. There is a critical need for molecular biomarkers that can provide more precise risk stratification to guide long-term monitoring.
Methodology
This study utilized a multi-stage approach to identify and validate novel biomarkers for post-SVR HCC risk.
Discovery and Validation
In the discovery phase, small RNA sequencing was performed on serum extracellular vesicles (EVs) from a cohort of 11 CHC patients at the 12-week post-treatment mark (SVR12). This cohort was divided into those who remained HCC-free and those who developed de novo or recurrent HCC. Following the identification of candidate miRNAs, a validation phase was conducted using a larger, independent cohort of 89 patients. miRNA levels were quantified using a specialized miRNA enzyme immunoassay (miREIA).
EV Characterization and Bioinformatics
To confirm the isolation of EVs, researchers employed Transmission Electron Microscopy (TEM) for morphology, Nanoparticle Tracking Analysis (NTA) for size distribution, and flow cytometry to detect surface markers such as CD63 and CD9. Bioinformatics tools, including Ingenuity Pathway Analysis, were used to predict the biological targets and functional pathways associated with the identified miRNAs.
Key Results
EV-miR-1-3p as a Protective Factor
The study identified serum EV-miR-1-3p as a significant protective factor. Unlike many biomarkers that increase with disease progression, higher levels of EV-miR-1-3p at the SVR12 baseline were strongly associated with a lower risk of future HCC development.
Superior Predictive Performance
EV-miR-1-3p outperformed traditional clinical markers in predicting both HCC occurrence and overall survival (OS):
- HCC Occurrence: EV-miR-1-3p achieved an Area Under the Curve (AUC) of 0.843, compared to 0.769 for AFP and 0.755 for the FIB-4 index.
- Overall Survival: The predictive power for OS was even more pronounced, with EV-miR-1-3p reaching an AUC of 0.876, while AFP (AUC 0.480) showed no significant predictive value.
Synergistic Risk Stratification
The combination of EV-miR-1-3p and AFP provided the most robust risk stratification. Patients characterized by low AFP (<10 ng/ml) and high EV-miR-1-3p levels demonstrated the lowest incidence of HCC. Conversely, the combination of high AFP and low EV-miR-1-3p identified the highest-risk group with 100% specificity in the study population.
Discussion
Mechanistically, bioinformatics analysis suggests that miR-1-3p functions as a tumor suppressor by targeting HSP90B1. HSP90B1 is a chaperone protein known to stabilize oncogenic pathways, including PI3K/AKT/mTOR and Hedgehog signaling. The downregulation of EV-miR-1-3p may therefore lead to the upregulation of these pathways, promoting oncogenesis even after viral clearance.
Clinical correlations further support these findings, as high baseline levels of EV-miR-1-3p were associated with better-preserved liver function, including higher albumin levels and platelet counts, as well as lower fibrosis scores.
Conclusion
Baseline serum EV-miR-1-3p represents a promising, non-invasive biomarker for predicting HCC development and survival in CHC patients after HCV eradication. By integrating this molecular marker with traditional clinical scores, clinicians can achieve more personalized and effective surveillance strategies in the post-SVR era. Future studies in larger, more diverse cohorts are warranted to confirm these findings across different ethnicities and HCV genotypes.
Summary updated